SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market activity following a favorable FDA meeting for its ANKTIVA + BCG bladder cancer application, which did not require new clinical trials, de-risking its path forward. The community is actively discussing a potential short squeeze, fueled by exceptionally high trading volume and strong conviction in the company's transformative cancer therapies. Investors are showing "diamond hands" as they anticipate further positive developments and a re-rating of the stock's value, pushing back against perceived short seller pressure.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending amid discussions of its strengthened position in the AI data center sector, following its recent full ownership of a key Texas data center campus and a strategic co-development partnership. The community is actively debating a potential short squeeze and eagerly awaiting an anchor tenant announcement for its hyperscale project, underscoring its perceived resilience despite past challenges.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is trending due to positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, which demonstrated significant efficacy and a favorable safety profile. The community is vigorously debating the stock's substantial surge, highlighting the drug's potential as a "best-in-class" oral therapy for a large market and speculating on future partnerships or a buyout. However, some investors express caution given the early-stage nature of the trial results and the historical tendency for Phase 1 catalysts to precede dilution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant licensing agreement with Pfizer for its Matrix-M adjuvant, validating the platform's potential and sparking widespread community discussion. This news, coupled with growing interest from other pharmaceutical companies, has heightened speculation of a short squeeze while also increasing pressure on management to deliver further strategic partnerships.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is trending due to its persistent decline, consistently hitting multi-year lows despite a generally positive market, leading to widespread shareholder frustration and calls for management accountability. Community discussions are heavily focused on CEO Jeff Green's perceived inaction and competitive pressures from 'walled garden' advertising platforms like Amazon. Investors are now keenly awaiting upcoming earnings as a potential make-or-break catalyst for the stock's direction.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently trending due to market reports indicating potential acquisition talks with Zydus Lifesciences, sparking widespread community discussion about a possible bidding war and future valuation. This comes on the heels of robust preliminary financial updates, including accelerated revenue projections for IBSRELA, now expected to reach a billion by 2029, and a significant patent extension to 2041 for its key products. Investors widely regard this extended intellectual property protection as a pivotal development, potentially driving a substantial re-rating and further M&A interest in the biotech sector.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is surging after being awarded a prime position on the U.S. Missile Defense Agency's SHIELD contract, enabling it to compete for critical task orders under the "Golden Dome" strategy. The community views this as a transformative catalyst, positioning INOD as a key player in government AI data training and potentially unlocking substantial future revenue from defense and global sovereign AI initiatives.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending intensely ahead of its upcoming earnings, with community sentiment highly polarized on whether strong content performance and recent strategic maneuvers, like the revised all-cash bid for Warner Bros. Discovery assets, will drive a significant rebound. Investors are closely debating the potential impact of these developments on subscriber growth and profitability, while also considering how broader market pressures and recent bond purchases by President Trump might influence the stock's post-earnings trajectory.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as new institutional developments, such as NYSE's tokenized securities platform, fuel optimism for its long-term utility, alongside record-high staking demand and near-zero unstaking queues. Despite this, community discussions are polarized, with debates centered on whether current market downturns and liquidations represent a prime buying opportunity or signal further weakness amidst broader crypto market volatility.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending due to its announced acquisition of a wine authentication and trading business, marking a strategic expansion into luxury wine products that fueled a notable rally. While many investors are celebrating significant recent gains and anticipating further momentum, others express caution, citing a recent share offering as potential dilution and debating the stock's long-term viability amidst "pump and dump" concerns.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Hold" by Analysts

Shares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have been assigned an average recommendation of "Hold" from the five brokerages that are currently covering the firm, MarketBeat Ratings...

Insider Buying: Annovis Bio (NYSE:ANVS) Director Buys 45,000 Shares of Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman bought 45,000 shares of the business's stock in a transaction dated Monday, December 8th. The stock was bought at an average...

Annovis Bio (NYSE:ANVS) Director Purchases $193,950.00 in Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman purchased 45,000 shares of the business's stock in a transaction dated Monday, December 8th. The shares were purchased at an...

Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) has earned a consensus recommendation of "Hold" from the five research firms that are covering the stock, MarketBeat reports. One investment analyst...

Michael Hoffman Acquires 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman purchased 39,200 shares of Annovis Bio stock in a transaction dated Monday, November 24th. The stock was bought at an average...

Michael Hoffman Buys 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman bought 39,200 shares of the company's stock in a transaction that occurred on Monday, November 24th. The shares were bought at...

Annovis Bio (NYSE:ANVS) Director Michael Hoffman Purchases 20,000 Shares

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman purchased 20,000 shares of the business's stock in a transaction dated Friday, November 21st. The stock was bought at an...

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 15,000 Shares of Stock

Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) Director Michael Hoffman acquired 15,000 shares of Annovis Bio stock in a transaction dated Friday, November 14th. The shares were bought at an average...

Best Penny Stocks To Watch Now - November 17th

Leap Therapeutics, Autonomix Medical, Cypherpunk Technologies, Annovis Bio, and Datavault AI are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are...

<ul class="summary-bullets"><li>The January meeting is intended to discuss the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD.&nbsp;</li><li>According to Annovis, PDD affects approximately 30% of Parkinson’s patients.&nbsp;</li><li>The company also said that its late-stage Alzheimer’s Disease study is ongoing with full regulatory alignment.</li></ul><p>Annovis Bio, Inc. (ANVS) on Tuesday said the U.S. Food and Drug Administration (FDA) has scheduled a January 2026 meeting to discuss the company's pathway to developing Buntanetap for the treatment of Parkinson's disease dementia.</p><p>Parkinson's disease dementia (PDD) is a type of dementia that occurs in people who already have Parkinson's disease, characterized by cognitive decline, such as memory problems and slowed thinking, along with the movement issues of PD. According to Annovis, PDD affects approximately 30% of Parkinson’s patients.</p><h2 class="st-heading-2">What Will Be Discussed At The Meeting?</h2><p>The meeting in January is aimed at discussing the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD, the company said. According to Annovis executive Cheng Fang, PDD is a natural extension of the company’s Alzheimer's and Parkinson's programs, wherein the company generated data demonstrating meaningful cognitive improvement with Buntanetap.</p><p>"The scheduled January meeting marks a key milestone for our pipeline, underscoring buntanetap's potential across multiple neurodegenerative indications and the strength of our scientific approach."<br>Maria Maccecchini, CEO, Annovis</p><h2 class="st-heading-2">Alzheimer’s Trial Progress</h2><p>The Malvern, Pennsylvania-headquartered company also said that its late-stage Alzheimer’s Disease study is ongoing with full regulatory alignment on study design, endpoints, and patient population.</p><p>The study is set to support applications for the drug in symptomatic treatment and disease-modifying treatment with Buntanetap.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p><a href="https://stocktwits.com/symbol/ANVS">ANVS shares</a> traded 16% higher at the time of writing. On Stocktwits, retail sentiment around ANVS remained in the ‘extremely bullish’ territory, while message volume remained at ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" width="624" height="61" alt="ANVS's Sentiment Meter and Message Volume as of 12:06 p.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>ANVS's Sentiment Meter and Message Volume as of 12:06 p.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure><p>ANVS stock fell 31% this year and by 49% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/waymo-announces-robotaxi-launch-in-five-more-cities/cLPV4fyRE7M">Waymo Announces Robotaxi Launch In Five More Cities</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Global stock market chart and trading board - stock photo

Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia

The meeting with the FDA is scheduled for January 2026. 

Equity

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Current Price	$2.82
Prev Close	$2.89
Open	$2.77
Dividend Yield	0.00%
50-Day Moving Average	$3.60
Beta	1.49
Avg. Volume	757,036.14
PE Ratio	-1.95

52-Week High	$5.50
52-Week Low	$1.11
Market Capitalization	$76.59M
EPS (Annual)	-$2.31
Price to Book	4.43
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ANVS
Annovis Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANVS News

ANVSAnnovis Bio Inc